clinical trial · NCT06579287
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
Sunhawk Vision Biotech, Inc.·phase2·active not recruiting·n = 140
Myopia, ProgressiveSHJ002Atropine
brief summary
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
started
Jan 22, 2025
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Jan 23, 2026
official title
A Phase II Study to Determine the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution on Myopia Control in Subjects Aged 3-12 Years.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol